Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-0302 and SHR-2554 in R/R PTCL
NCT06519526Phase 2Recruiting
- Sponsor
- Fudan University
- Start
- Aug 2024
- Primary completion
- Feb 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of ivarmacitinib and zeprumetostat in peripheral T-cell lymphoma (PTCL) (2 cohorts), sponsored by Fudan University. Primary endpoints: Incidence and severity of Adverse Events and Serious Adverse Events and Objective Response Rate at 24 months. Started Aug 2024; status: recruiting.
02
Drugs
ivarmacitinibzeprumetostat
03
Conditions
peripheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on NCT06519526.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06519526.